|
Q3 2024
|
3 |
1,123 |
CSTL, AADI, SYBX
|
13F-HR
|
11/14/2024 |
000095012324011462 |
|
Q2 2024
|
3 |
859 |
CSTL, AADI, SYBX
|
13F-HR
|
8/14/2024 |
000095012324008425 |
|
Q1 2024
|
3 |
831 |
CSTL, AADI, SYBX
|
13F-HR
|
5/15/2024 |
000095012324005237 |
|
Q4 2023
|
3 |
899 |
CSTL, AADI, SYBX
|
13F-HR
|
2/14/2024 |
000095012324002145 |
|
Q3 2023
|
3 |
735 |
CSTL, AADI, SYBX
|
13F-HR
|
11/14/2023 |
000095012323010775 |
|
Q2 2023
|
3 |
732 |
CSTL, AADI, SYBX
|
13F-HR
|
8/14/2023 |
000095012323008143 |
|
Q1 2023
|
3 |
1,087 |
CSTL, AADI, SYBX
|
13F-HR
|
5/15/2023 |
000095012323005000 |
|
Q4 2022
|
4 |
1,309 |
CSTL, AADI, SYBX, HXXB.MU
|
13F-HR
|
2/14/2023 |
000095012323002335 |
|
Q3 2022
|
5 |
1,475 |
CSTL, AADI, SYBX, HXXB.MU
|
13F-HR
|
11/14/2022 |
000095012322011712 |
|
Q2 2022
|
6 |
1,344 |
CSTL, AADI, SYBX, HXXB.MU
|
13F-HR
|
8/15/2022 |
000095012322009127 |
|
Q1 2022
|
5 |
1,463 |
SYBX, GNCA, AADI, HXXB.MU
|
13F-HR
|
5/16/2022 |
000095012322005935 |
|
Q4 2021
|
6 |
1,729 |
AADI, SYBX, GNCA, LUNG
|
13F-HR
|
2/14/2022 |
000095012322002414 |
|
Q3 2021
|
6 |
2,407 |
AADI, GNCA, SYBX, LUNG
|
13F-HR
|
11/15/2021 |
000095012321015125 |
|
Q2 2021
|
7 |
29,870 |
AVIR, GNCA, SYBX, AERPIO PHARMACEUTICALS INC
|
13F-HR
|
8/16/2021 |
000095012321011102 |
|
Q1 2021
|
7 |
203,504 |
ATEA PHARMACEUTICALS INC, LUNG, GNCA, SYBX
|
13F-HR
|
5/17/2021 |
000095012321006752 |
|
Q4 2020
|
7 |
169,844 |
AVIR, LUNG, GNCA, SYBX
|
13F-HR
|
2/16/2021 |
000095012321002372 |